|
| 37386588 | A gene signature can predict risk of MGUS progressing to multiple myeloma. | | 2023 |
| 37591845 | Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. | | 2023 |
| 38052037 | Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up. | | 2023 |
| 35329966 | Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. | Journal of Clinical Medicine | 2022 |
| 35881476 | CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. | Journal of Clinical Investigation | 2022 |
| 35922426 | The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. | Nature Communications | 2022 |
| 36513657 | Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. | Nat Commun | 2022 |
| 34670732 | Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35013207 | Functional dissection of inherited non-coding variation influencing multiple myeloma risk. | Nat Commun | 2022 |
| 34365473 | Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. | Leukemia | 2022 |
| 34244996 | High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. | British Journal of Haematology | 2021 |
| 33894670 | PHF19 inhibition as a therapeutic target in multiple myeloma. | Current Research in Translational Medicine | 2021 |
| 33436579 | The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. | Nature Communications | 2021 |
| 31375765 | Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma. | Modern Pathology | 2020 |
| 32265150 | Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 31900879 | Hemophagocytic relapsed intramedullary plasmacytoma. | | 2020 |
| 31990333 | Long-term outcomes after autologous stem cell transplantation for multiple myeloma. | Blood advances | 2020 |
| 32393732 | Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem | Blood Cancer Journal | 2020 |
| 31988198 | and Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. | Clinical Cancer Research | 2020 |
| 33147277 | Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. | PLoS Med | 2020 |
| 32816893 | Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. | Clinical Cancer Research | 2020 |
| 32555163 | Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. | Blood Cancer Journal | 2020 |
| 32660906 | Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 31367255 | Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis? | Theranostics | 2019 |
| 31805192 | Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. | Blood advances | 2019 |
| 30408155 | Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. | British Journal of Haematology | 2019 |
| 30573775 | Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. | Leukemia | 2019 |
| 30279229 | Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia. | Clinical Cancer Research | 2019 |
| 31084780 | PET-Computed Tomography in Myeloma: Current Overview and Future Directions. | PET Clinics | 2019 |
| 31399558 | An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. | Blood Cancer Journal | 2019 |
| 29784643 | The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. | Blood | 2018 |
| 28642592 | Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. | Leukemia | 2018 |
| 29980678 | Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. | Blood Cancer Journal | 2018 |
| 29929441 | Imipridone ONC201: combination therapy in hematologic malignancies. | Cell Cycle | 2018 |
| 30337321 | Walking on myeloma. | Blood | 2018 |
| 30241189 | Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia. | Journal of global oncology | 2018 |
| 30470751 | Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. | Blood Cancer Journal | 2018 |
| 29945937 | Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. | Blood Adv | 2018 |
| 30619976 | Daratumumab-induced transient myopic shift. | Am J Ophthalmol Case Rep | 2018 |
| 29669929 | Antigen-mediated regulation in monoclonal gammopathies and myeloma. | JCI insight | 2018 |
| 29567784 | Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. | Haematologica | 2018 |
| 29563136 | The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. | Clinical Cancer Research | 2018 |
| 29122646 | Drug response prediction in high-risk multiple myeloma. | Gene | 2018 |
| 28234347 | Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. | Blood Cancer J | 2017 |
| 28432222 | Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. | Blood | 2017 |
| 28863804 | Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. | Lancet Haematology,The | 2017 |
| 28550191 | The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma. | Haematologica | 2017 |
| 28427158 | The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. | Oncotarget | 2017 |
| 28814763 | Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. | Nature Communications | 2017 |
| 28383130 | Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. | American Journal of Hematology | 2017 |